New research reveals that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Findings released in a prominent health publication shows that while obese individuals frequently drop about a fifth of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People buying such treatments should be aware of the potential of quick weight regain when the medication concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting mass within about one and a half years.
Weighing Approaches
The research, which examined dozens of studies involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
Scientists emphasize that people who lose weight through dieting generally experience a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Experts believe the mode of action of the drugs is key to understanding the amplified regain.
These medications copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the body to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means hunger is no longer kept in check, making overeating far more likely."
A Lifelong Issue?
Health authorities advise the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the high risk of relapse, the therapy should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
Individuals who have discontinued the jabs describe a intense return of cravings.
"It was like something that goes on and you become extremely hungry," recalled one woman.
This challenge is exacerbated if patients have not adopted permanent lifestyle or habit changes during therapy.
Significant Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while these medications are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss likely depends on combined lifestyle support.
